The European Medicines Agency (EMA), Europe's medicines regulator, said on 12 January 2021 that it received an application from British pharmaceutical company AstraZeneca for the conditional approval of the company's COVID-19 vaccine being developed along with the University of Oxford, Reuters news agency reported on Tuesday.
The EMA has said it would assess the application under an accelerated timeline.
In a statement, during the meeting of the European Medicines Agency's (EMA) human medicines committee (CHMP), the EMA said an opinion on the conditional marketing authorisation could be issued by 29 January 2021.
The EMA also said that during its rolling review of the vaccine, it had assessed data from ongoing trials in Britain, Brazil and South Africa.
Additional information was also provided by AstraZeneca at the request of CHMP and is currently being studied, the EMA added.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT